The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.